 Abstract androgen deprivation therapy, ADT, is a common treatment for prostate cancer, but it does not always work. When it fails, the disease becomes resistant and can no longer be treated with ADT alone. Researchers have now identified a new mechanism that allows prostate cancer cells to become resistant to ADT. They found that the tumor suppressor gene PTEN is essential for the development of prostate cancer, and when this gene is deleted in mice, the mice develop prostate cancer that is resistant to ADT. The researchers also discovered that the tumors express high levels of a protein called HIF-1A, which is involved in regulating blood flow and oxygen levels in the body. By blocking HIF-1A, they were able to reverse the resistance to ADT in these mice. This suggests that drugs that block HIF-1A could be used to treat patients whose prostate cancer has become resistant to ADT. This article was authored by Julie Terzik, Mohamed A. Abu El-Mati, Regis Lipsing, and others. We are article.tv, links in the description below.